Well I'm certainly not yawning.
Yes, still relatively early stage and patient numbers are small, but the data to date looks impressive to me.
While the primary endpoint for next year's pivotal trial is still to be chosen – it could be improvement in low-luminance visual acuity (LLVA) as measured by eye chart or it could be improvement in retinal sensitivity and/or number of scotomas as measured by microperimetry – but clear improvement is already being seen on all of these measures.
I also note that there are plans to discuss the potential for accelerated approval with the FDA in H1 next year.
Ann: Presentation of RP11 Clinical Trial Data at APVRS 2024, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |